Your browser doesn't support javascript.
loading
Toxicokinetics of a urinary metabolite of tebuconazole following controlled oral and dermal administration in human volunteers.
Oerlemans, A; Verscheijden, L F M; Mol, J G J; Vermeulen, R C H; Westerhout, J; Roeleveld, N; Russel, F G M; Scheepers, P T J.
Afiliación
  • Oerlemans A; Radboud Institute for Health Sciences, Radboud University Medical Center, P.O. Box. 9101, 6500 HB, Nijmegen, The Netherlands. arne.oerlemans@radboudumc.nl.
  • Verscheijden LFM; Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Mol JGJ; Wageningen Food Safety Research, Wageningen University and Research, Wageningen, The Netherlands.
  • Vermeulen RCH; Institute for Risk Assessment Sciences, University Utrecht, Utrecht, The Netherlands.
  • Westerhout J; TNO, Zeist, The Netherlands.
  • Roeleveld N; Radboud Institute for Health Sciences, Radboud University Medical Center, P.O. Box. 9101, 6500 HB, Nijmegen, The Netherlands.
  • Russel FGM; Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Scheepers PTJ; Radboud Institute for Health Sciences, Radboud University Medical Center, P.O. Box. 9101, 6500 HB, Nijmegen, The Netherlands.
Arch Toxicol ; 93(9): 2545-2553, 2019 09.
Article en En | MEDLINE | ID: mdl-31359083
ABSTRACT
Tebuconazole (TEB) is a widely used triazole fungicide, but the toxicokinetics of its human metabolites are not fully described. For proper interpretation of biological monitoring data, knowledge on the metabolism and elimination of the compound is required. A human volunteer study was performed with the aim to describe the time courses of urinary excretion after controlled oral and dermal administration of TEB. Six healthy volunteers (three males and three females) received on separate occasions a single oral dose of 1.5 mg of TEB and a single dermal dose of 2.5 mg during 1 h. In addition to a pre-exposure urine sample, complete urine voids were collected over 48 h post-administration. The main metabolite hydroxy-tebuconazole (TEB-OH) was quantified in each urine sample. Peak excretion rates after oral and dermal administration were reached after 1.4 and 21 h, mean elimination half-lives were 7.8 and 16 h, and recoveries within 48 h were 38% and 1%, respectively. The time courses of excretion were compared to simulations with an established physiologically based toxicokinetic model for TEB that was extended with a parallel model for TEB-OH. Overall, TEB-OH was rapidly excreted into urine after oral exposure, and renal elimination was considerably slower after dermal exposure. Urinary time courses between individuals were similar. The model predictions were in good agreement with the observed time courses of excretion.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Triazoles / Fungicidas Industriales / Modelos Biológicos Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Arch Toxicol Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Triazoles / Fungicidas Industriales / Modelos Biológicos Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Arch Toxicol Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos